NASDAQ · Financial Statements

Jazz Pharmaceuticals plc (JAZZ) Revenue, Earnings & Financial Statements

$240.71 NASDAQ: JAZZ Market Cap $15.45B

Data as of Nov 17, 2026 close · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Jazz Pharmaceuticals plc most recently reported annual revenue of $4.3B, a net loss of $356.0M. Revenue grew at an average annual rate of 12.5% over the last 5 fiscal years. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Jazz Pharmaceuticals plc: Revenue rose from $1.5B in 2016 to $4.3B in 2025, a change of +186.8% over 9 years; net profit was positive in 7 of 10 reported years; operating margin moved from 39.8% to 5.3%, a shift of -34.5 percentage points; the most recent year shows a net loss of $356.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$1.5B$1.6B$1.9B$2.2B$2.4B$3.1B$3.7B$3.8B$4.1B$4.3B
Operating Expenses$896.0M$1.1B$1.3B$1.6B$2.0B$2.9B$3.7B$3.3B$3.4B$4.0B
Operating Profit$592.0M$529.0M$615.0M$532.0M$378.0M$170.0M−$66.0M$579.0M$717.0M$224.0M
Operating Margin39.8%32.7%32.5%24.6%16.0%5.5%-1.8%15.1%17.6%5.3%
Other Income−$60.0M−$89.0M−$88.0M−$82.0M−$106.0M−$284.0M−$317.0M−$284.0M−$248.0M−$853.0M
Interest$62.0M$78.0M$79.0M$72.0M$100.0M$279.0M$288.0M$289.0M$238.0M$195.0M
Depreciation$114.0M$165.0M$217.0M$370.0M$278.0M$552.0M$629.0M$639.0M$660.0M$696.0M
Profit Before Tax$532.0M$440.0M$527.0M$450.0M$272.0M−$114.0M−$383.0M$295.0M$469.0M−$629.0M
Tax rate (%)25.4%-10.8%15.2%-16.3%12.3%-190.3%41.5%-40.7%-19.5%43.3%
Net Profit$397.0M$488.0M$447.0M$523.0M$239.0M−$329.0M−$224.0M$415.0M$560.0M−$356.0M
EPS$6.41$7.96$7.30$9.09$4.22−$5.51−$3.58$6.10$8.65−$5.84

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricDec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26Sep '26
Revenue$1.0B$902.0M$1.0B$1.1B$1.1B$898.0M$1.0B$1.1B$1.2B$1.1B$1.2B$1.2B
Operating Expenses$889.0M$836.0M$824.0M$795.0M$897.0M$954.0M$1.7B$1.1B$289.0M$855.0M$960.0M$1.7B
Operating Profit$122.0M$66.0M$199.0M$260.0M$191.0M−$56.0M−$686.0M$58.0M$909.0M$214.0M$248.0M−$413.0M
Operating Margin12.1%7.3%19.5%24.7%17.5%-6.2%-65.6%5.1%75.9%20.0%20.5%-33.3%
Interest$70.0M$66.0M$62.0M$59.0M$51.0M$54.0M$47.0M$49.0M$45.0M$63.0M$37.0M$46.0M
Profit Before Tax$61.0M−$3.0M$138.0M$201.0M$133.0M−$110.0M−$736.0M$9.0M$208.0M$299.0M$211.0M−$459.0M
Tax rate (%)-54.2%-395.7%-22.2%-7.3%-43.5%16.1%2.3%-2683.2%2.3%2.0%8.6%-5.3%
Net Profit$94.0M−$15.0M$169.0M$215.0M$191.0M−$93.0M−$718.0M$251.0M$203.0M$293.0M$193.0M−$483.0M
EPS$1.42−$0.23$2.49$3.42$3.11−$1.52−$11.74$4.08$3.34$4.43$2.78−$7.48

Over the 10 years reported for Jazz Pharmaceuticals plc, borrowings increased from $2.0B in 2016 to $5.4B in 2025, cash stood at $1.4B in the latest year, shareholders' equity was $0, current assets covered current liabilities 1.86 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$4.8B$5.1B$5.2B$5.5B$6.5B$12.3B$10.8B$11.4B$12.0B$11.7B
Current Assets$748.0M$968.0M$1.2B$1.6B$2.8B$2.6B$2.6B$3.4B$4.6B$4.2B
Cash$366.0M$386.0M$310.0M$637.0M$1.1B$591.0M$881.0M$1.5B$2.4B$1.4B
Inventory$34.0M$43.0M$53.0M$79.0M$95.0M$1.1B$714.0M$597.0M$480.0M$417.0M
Receivables$234.0M$224.0M$264.0M$356.0M$396.0M$563.0M$651.0M$706.0M$717.0M$831.0M
Fixed Assets$107.0M$170.0M$200.0M$271.0M$257.0M$343.0M$301.0M$235.0M$227.0M$259.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$60.0M$215.0M$515.0M$440.0M$1.1B$5.0M$6.0M$120.0M$584.0M$1.1B
Other Assets$894.0M$948.0M$928.0M$920.0M$958.0M$1.8B$1.7B$1.8B$1.7B$1.8B
Total Liabilities$2.9B$2.4B$2.4B$2.4B$2.9B$8.3B$7.8B$7.7B$7.9B$7.3B
Current Liabilities$257.0M$294.0M$345.0M$364.0M$654.0M$809.0M$933.0M$1.5B$1.0B$2.2B
Borrowings$2.0B$1.6B$1.6B$1.8B$2.2B$6.2B$5.8B$5.8B$6.2B$5.4B
Other Liabilities$893.0M$830.0M$850.0M$657.0M$627.0M$2.2B$1.9B$1.9B$1.8B$1.9B
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$1.9B$2.7B$2.8B$3.1B$3.7B$4.0B$3.1B$3.7B$4.1B$4.3B

For Jazz Pharmaceuticals plc, operating cash flow was positive in 10 of 10 reported years; free cash flow in the latest year was $1.1B; free cash flow was positive in 10 of 10 years; financing activities used $200.0M in the latest year, which covers debt repayment, dividends and buybacks.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$591.0M$693.0M$799.0M$776.0M$900.0M$779.0M$1.3B$1.1B$1.4B$1.4B
Investing Cash Flow−$1.9B−$383.0M−$526.0M−$338.0M−$1.4B−$5.3B−$944.0M−$187.0M−$556.0M−$1.7B
Financing Cash Flow−$254.0M−$82.0M−$547.0M−$318.0M−$47.0M−$36.0M−$45.0M−$321.0M−$375.0M−$200.0M
Net Cash Flow−$623.0M$20.0M−$76.0M$328.0M$420.0M−$466.0M$290.0M$625.0M$907.0M−$1.0B
Free Cash Flow$409.0M$579.0M$667.0M$594.0M$520.0M$733.0M$774.0M$1.1B$1.3B$1.1B

Valuation & Return Ratios

MetricValue
PEG Ratio0.04
EV / EBITDA16.71
FCF Yield9.87%
Quick Ratio1.64
Interest Coverage5.01
Return 1Y41.52%
Return 3Y99.66%
Return 5Y84.71%

Jazz Pharmaceuticals plc (JAZZ) financials — frequently asked questions

What is Jazz Pharmaceuticals plc's annual revenue?

Jazz Pharmaceuticals plc (JAZZ) reported annual revenue of $4.3B in its most recent fiscal year.

What is Jazz Pharmaceuticals plc's net profit?

Jazz Pharmaceuticals plc (JAZZ) reported a net loss of $356.0M in its most recent fiscal year.

What is JAZZ EV/EBITDA?

Jazz Pharmaceuticals plc's enterprise value to EBITDA (EV/EBITDA) ratio is 16.71.

Revenue and earnings of other Biotechnology stocks

VRTX revenue $12.1BREGN revenue $14.3BMRNA revenue $1.9BRVMD financialsROIV revenue $8.0MINSM revenue $606.0MUTHR revenue $3.2BINCY revenue $5.1BALNY revenue $3.7BASND revenue $692.0MAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
JAZZ Overview JAZZ Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.